Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Salanoubat

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Leukemia & Lymphoma|March 18, 2000
Is mantle cell lymphoma a sex-related disease?D Decaudin, C Salanoubat, P Carde
Revue Medicale Suisse|November 24, 2006
[Chronic lymphoid B-cell leukemia]C Salanoubat, A Delmer, J P Marie
Leukemia|June 23, 2006
Hyperforin, a new lead compound against the progression of cancer and leukemia?C Quiney, C Billard, C Salanoubat, et al.
Leukemia|January 21, 2006
Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemiaC Quiney, C Billard, A M Faussat, et al.
Leukemia Research|December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?R Itzykson, S Thépot, O Beyne-Rauzy, et al.
Blood Cancer Journal|May 13, 2017
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agentsM Duchmann, T Braun, J-B Micol, et al.
Leukemia & Lymphoma|February 18, 2021
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemiaS Fodil, E Raffoux, P Y Dumas, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Leukemia & Lymphoma|March 18, 2000
Is mantle cell lymphoma a sex-related disease?D Decaudin, C Salanoubat, P Carde
Revue Medicale Suisse|November 24, 2006
[Chronic lymphoid B-cell leukemia]C Salanoubat, A Delmer, J P Marie
Leukemia|June 23, 2006
Hyperforin, a new lead compound against the progression of cancer and leukemia?C Quiney, C Billard, C Salanoubat, et al.
Leukemia|January 21, 2006
Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemiaC Quiney, C Billard, A M Faussat, et al.
Leukemia Research|December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?R Itzykson, S Thépot, O Beyne-Rauzy, et al.
Blood Cancer Journal|May 13, 2017
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agentsM Duchmann, T Braun, J-B Micol, et al.
Leukemia & Lymphoma|February 18, 2021
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemiaS Fodil, E Raffoux, P Y Dumas, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
Pageof 1